MicroRNA-125a-3p modulate amyloid β-protein through the MAPK pathway in Alzheimer's disease

CONCLUSION: Our study indicates that targeting miR-125a-3p may be an applicable therapy for AD in the future. However, more in vitro and in vivo studies with more samples are needed to confirm these results.PMID:37711111 | DOI:10.2174/1567205020666230913105811

Source: Current Alzheimer Research - September 15, 2023 Category: Neurology Authors: Xi-Chen Zhu Meng-Zhuo Zhu Jing Lu Qing-Yu Yao Jia-Wei Hu Wen-Jun Long Sha-Sha Ruan Wen-Zhuo Dai Rong Li Source Type: research